Corona Vaccine: DCGI approves to launch Covax in the market, expert committee recommends

The Drug Controller General of India (DCGI) has approved the COVID-19 vaccine Covax to be marketed as a heterologous booster dose for adults. Covax can be given to adults who have been given two doses of Covishield or Covaxin. Official sources have given information about this on Monday.

Wrote a letter to DCGI

The DCGI's approval comes after the recommendation of the subject expert committee of the Central Drugs Standard Control Organization (CDSCO). Prakash Kumar Singh, Director, of Government, and Regulatory Affairs, Serum Institute of India (SII) recently wrote to DCGI for approval of Covovax Heterologous Booster Dose for those aged 18 years and above because of the growing COVID-19 pandemic.

Expert committee recommended

An official source said the subject expert committee of the CDSCO deliberated on the issue on Wednesday and recommended the launch of Covax as a contrasting booster dose for adults who have taken two doses of Covishield or Covaxin. DCGI approved Covax for use in emergencies for adults on 28 December 2021.

DCGI-approved emergency use

In addition, the DCGI approved Covax for emergency use on March 9, 2022, in the age group of 12-17 years, and on June 28 last year, in the age group of 7-11 years, with certain conditions. Explain that Covax is manufactured through technology transfer from Novavax. It has been approved by the European Medicines Agency for conditional marketing authorization. The World Health Organization (WHO) listed it as an emergency on 17 December 2021.

Also Read: China: Retrenchment in China after Corona, employees of COVID test kit manufacturer Zybio protest